Bio-Techne Corp (TECH) is set to have a significant presence, presenting at many prestigious events such as the 27th Annual Meeting of the American Society of Gene & Cell and the Barclays 26th Annual Global Healthcare Conference. Noticeably, the company's financial performance is drawing attention, with Q2 and Q3 of fiscal 2024 showing mixed results amid industry challenges. Irrespective of such hurdles, its share price is projected to be 32% above the intrinsic value estimate, while its price target was also raised to $81.00.
A promising development is TECH's recent partnership with Nikon Instruments Inc, expanding access to its innovative solutions. Simultaneously, The company has secured a new distribution agreement with Thermo Fisher Scientific as well as being involved in various investments, such as its completion in Wilson Wolf Manufacturing.
Meanwhile, TECH continues to show robustness, with Russell Investments Group Ltd. and GAMMA Investing LLC increasing their stock holdings. Despite slight EPS miss, analysts remain bullish about the company's future. The company also recently declared a dividend and announced new executive appointments, indicating strong leadership and corporate governance.<\/p>
Bio-Techne Corp TECH News Analytics from Wed, 03 Mar 2021 08:00:00 GMT to Tue, 07 May 2024 11:17:24 GMT - Rating 6 - Innovation 7 - Information 8 - Rumor -2
